QHL-1618

Phase Ia study to evaluate the safety and tolerability of ALK-N001 for injection in patients with advanced solid tumors; to determine the recommended Phase II dose (RP2D) of ALK-N001 for injection and/or maximum tolerated dose (MTD); evaluate the human pharmacokinetic characteristics of ALK-N001 for injection under different dosing regimens and obtain preliminary pharmacokinetic parameters (PK); preliminarily evaluate the effectiveness of ALK-N001 for injection in patients with advanced solid tumors; identify the metabolites of ALK-N001 for injection in the blood (if applicable); Phase Ib/II evaluation of the effectiveness of ALK-N001 for injection in patients with advanced solid tumors such as esophageal squamous cell carcinoma, small cell lung cancer, and gastric/esophagogastric junction adenocarcinoma; further evaluate the safety of ALK-N001 for injection in patients with advanced solid tumors such as esophageal squamous cell carcinoma, small cell lung cancer, and gastric/esophagogastric junction adenocarcinoma; further evaluate the PK parameters of ALK-N001 for injection in patients with esophageal squamous cell carcinoma, small cell lung cancer, and gastric/esophagogastric junction adenocarcinoma; identify the metabolites of ALK-N001 for injection in the blood (if applicable)